Last updated on: 26/06/2013
1. Contact details
Name of network/collaboration (full name) PROTECT
Network/collaboration (short name)PROTECT
Website/homepagewww.imi-protect.eu 
Primary contact point of network/collaboration
1) Department/research groupEuropean Medicines Agency
2) Organisation/affiliation 
Administrative Contact
Title Miss
Last name Leszczynska
First name Malgorzata
Address line 17 Westferry Circus
Address line 2Canary Wharf 
Address line 3 
CityLondon 
PostcodeE14 4HB 
CountryUnited Kingdom
Phone number (incl. country code)44-207523 7631  
Alternative phone number 
Fax number (incl. country code)44-2074188668 
Email address malgorzata.leszczynska@ema.europa.eu
Scientific Contact
Title Dr
Last name Kurz
First name Xavier
Address line 17 Westferry Circus
Address line 2Canary Wharf 
Address line 3 
CityLondon 
PostcodeE14 4HB 
CountryUnited Kingdom
Phone number (incl. country code)44-2075237269 
Alternative phone number 
Fax number (incl. country code)44-2074188668 
Email address xavier.kurz@ema.europa.eu
2. Description
PROTECT is a public-private European project funded by the Innovative Medicines Initiative Joint Undertaking. It comprises a 5 year research programme to address limitations of current methods in the field of pharmacoepidemiology and pharmacovigilance. The European Medicines Agency is the coordinator and Glaxo Smith Kline is the deputy coordinator of this multi-national consortium of 31 partners. The goal is to strengthen the monitoring of the benefit/risk of medicines in Europe. This will be achieved by developing a set of innovative tools and methods to improve the early detection of safety signals, enhance direct data collection from consumers and provide for a continous benefit/risk monitoring of medicines. In addition, a methodological framework of pharmacoepidemiology studies will be developed aiming at increasing the usefulness and reliability of these studies for benefit/risk assessment. All methods will be tested to demonstrate their usefulness and applicability.
Top